Luminex and Abbott Sign Agreement for Global Distribution of the xTAG(TM) Respiratory Viral Panel
29 February 2008 - 9:13AM
Business Wire
Luminex Molecular Diagnostics, a division of Luminex Corporation
(NASDAQ: LMNX), the worldwide leader in multiplexing solutions, has
signed a global sales and distribution agreement with Abbott�s
(NYSE: ABT) molecular diagnostics business. Under the terms of the
agreement, Abbott will have exclusive rights to distribute
Luminex�s new xTAGTM Respiratory Viral Panel (RVP) worldwide
outside the United States and semi-exclusive rights in the United
States. Based on Luminex�s xMAP� multiplexing technology, xTAG RVP
was created by Luminex Molecular Diagnostics, in partnership with a
team of leading virologists and infectious disease specialists. In
a matter of hours from a single patient sample, the test allows
doctors to detect the presence or absence of several viruses and
subtypes at once. �We believe that xTAG RVP has the potential to
significantly impact the detection, treatment, and control of
respiratory viruses worldwide,� said Douglas Bryant, executive vice
president and chief operating officer of Luminex. �Abbott�s
long-standing dedication to improve the quality of human health,
combined with their global customer base, will make them a strong
partner in bringing xTAG RVP to more physicians, public health
authorities and patients around the world.� xTAG RVP received
510(k) clearance by the U.S. Food and Drug Administration in
January 2008, and became CE marked for sale in Europe in November
2006. In the United States, xTAG RVP has been cleared to detect 12
viruses and viral subtypes: Adenovirus Influenza A (all subtypes)
Influenza A H1 Influenza A H3 Influenza B Metapneumovirus
Parainfluenza 1 Parainfluenza 2 Parainfluenza 3 Respiratory
syncytial virus (RSV) A Respiratory syncytial virus (RSV) B
Rhinovirus In Europe, xTAG RVP is certified to detect and identify
20 viruses and viral subtypes � including the targets above, plus:
Corona Virus 229E Corona Virus HKU1 Corona Virus NL63 Corona Virus
OC43 Enterovirus Influenza A H5 Parainfluenza 4 SARS For more
information on the xTAG RVP, please visit www.luminexcorp.com/rvp.
About Luminex Corporation Luminex Corporation develops,
manufactures and markets proprietary biological testing
technologies with applications throughout the diagnostic and life
sciences industries. The Company's xMAP� multiplex solutions
include an open-architecture, multi-analyte technology platform
that delivers fast, accurate and cost-effective bioassay results to
markets as diverse as pharmaceutical drug discovery, clinical
diagnostics and biomedical research, including the genomics and
proteomics research markets. The Company's xMAP technology is sold
worldwide and is already in use in leading clinical laboratories as
well as major pharmaceutical, diagnostic and biotechnology
companies. Further information on Luminex Corporation or xMAP
technology can be obtained at www.luminexcorp.com.
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Luminex Corporation (NASDAQ): 0 recent articles
More Luminex Molecular Diagnostics News Articles